Improving treatment for pneumonia caused by drug-resistant bacteria
Official title: Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa
Funded at Taxis Pharmaceuticals, INC. · NIH-11080358 · Data updated 2026-11-12
This study is testing a new treatment that combines a special compound with an antibiotic to help fight tough infections like hospital-acquired pneumonia and ventilator-associated pneumonia caused by resistant bacteria, and it could help patients get better faster.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Taxis Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Monmouth Junction, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $889,610 |
| NIH project number | 5R44AI174351-02 |
| Project ID | NIH-11080358 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with hospital-acquired pneumonia or ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.
✕Less likely to help
Patients with pneumonia caused by non-resistant strains of bacteria or those with other unrelated respiratory conditions may not benefit from this research.
What this research studies
This research focuses on developing a new treatment approach for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) caused by multidrug-resistant Pseudomonas aeruginosa. The team is working on a novel efflux pump inhibitor (EPI) that, when combined with the antibiotic levofloxacin, aims to enhance the effectiveness of the treatment by preventing the bacteria from expelling the drug. The research involves testing a specific compound, TXA14007, which has shown promise in laboratory studies by improving the potency of levofloxacin against resistant bacterial strains. Patients may benefit from this innovative approach if it leads to more effective therapies for these serious infections.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from severe pneumonia caused by drug-resistant bacteria.
How similar studies have gone: Previous research has shown promise in using efflux pump inhibitors to enhance antibiotic efficacy, indicating potential success for this novel approach.
Where this research is happening
-
Taxis Pharmaceuticals, INC.
Monmouth Junction, United States Active
Researchers
- Principal investigator: Parhi, Ajit K — Taxis Pharmaceuticals, INC.
- Study coordinator: Parhi, Ajit K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.